Financial Data and Key Metrics Changes - Fourth Quarter revenue was $229 million, up 11% year over year, at the high end of guidance [5][6] - Non-GAAP gross margin for the Fourth Quarter was 34%, 130 basis points higher than the same quarter last year [6][14] - Non-GAAP earnings per share in the Fourth Quarter was $0.37, up $0.21 compared to last year [6] - Total revenue for Fiscal Year 2025 was $845 million, a 4% increase compared to Fiscal Year 2024 [6] - Non-GAAP EBITDA for the year was $122 million, up $33 million from $89 million last year [6][15] Business Line Data and Key Metrics Changes - Medical segment revenue increased by 5% year over year, totaling $152 million in the Fourth Quarter [11][12] - Industrial segment revenue grew by 25% year over year, reaching $77 million in the Fourth Quarter, marking the highest quarterly contribution of industrial revenue in Varex's history [11][12] - For the full fiscal year, medical revenue was $593 million, a 2% increase year over year, while industrial revenue was $252 million, a 10% increase [6][11] Market Data and Key Metrics Changes - Revenue from the Americas grew by 9%, EMEA rose by 16%, and APAC increased by 8% year over year [13] - Sales volume to China remained steady, contributing 14% of total revenues, reflecting resilience in the healthcare market despite tariff challenges [13][21] Company Strategy and Development Direction - The company plans to invest in R&D to strengthen its competitive edge and focus on growth markets such as India, South Asia, the Middle East, and Latin America [22][23] - Varex is advancing its photon counting CT technology and expanding its manufacturing capabilities in India to support cost-effective product designs [22][23][25] - The company aims to lead with innovation while maintaining cost-effectiveness in the value and mid-tier segments [22] Management's Comments on Operating Environment and Future Outlook - Management noted a challenging start to Fiscal Year 2025 due to global tariff situations, but customer ordering patterns have normalized [21] - Customers in China are projecting stronger orders for 2026 compared to 2024 and 2025, driven by demand for value tier and mid-tier CT systems [21] - The company is intensifying efforts to strengthen geopolitical resiliency through supply chain and manufacturing regionalization [21][22] Other Important Information - The company ended the year with $155 million in cash, cash equivalents, and marketable securities, down from $213 million last year due to debt retirement [6][18] - Gross debt outstanding at the end of the quarter was $370 million, with a net debt leverage ratio of approximately 1.8 times adjusted EBITDA [18][19] Q&A Session Summary Question: Can you split the top 10 customers' contribution between medical and industrial? - Management stated that the top 10 customers generally account for 50%-55% of sales, primarily from the medical segment, but they do not disclose the split for commercial reasons [30][31] Question: Is there a structural shift in the medical and industrial segments? - Management indicated that industrial sales are growing and expected to reach mid-30s as a percentage of overall sales, while medical segment volatility is influenced by geopolitical factors [32][33] Question: What are the implications of GE and Siemens Healthineers divesting their China business? - Management noted that most business in China comes through Chinese OEMs, so these announcements do not have significant implications for Varex [36][37] Question: Can you provide a high-level outlook for the full year? - Management expects solid demand and growth in both medical and industrial segments, with medical business ex-China anticipated to grow [40][41] Question: What is the impact of tariffs on gross margin? - Management indicated that tariffs impact gross margin by 100 to 150 basis points, and they are working to mitigate this through supply chain adjustments [82][83]